|
|
Hematology, Oncology and
Bone Marrow Transplantation
Research
The Hematology, Oncology and Bone Marrow Transplantation faculty are strongly committed to research in their specialized fields.
Drs. Edythe Albano and Brian Greffe participate in several Children's Oncology Group committees, including acute leukemia, osteosarcoma, germ cell tumors, soft tissue sarcomas and late effects. Dr. Kelly Maloney is Co-Chair of the Standard Risk ALL (Acute Lymphoblastic Leukemia) Committee of the Children's Oncology Group. Drs. Roger Giller and Ralph Quinones collaborate with the adult Bone Marrow Transplantation Program at University of Colorado Hospital on ex vivo expansion of umbilical-cord-derived hematopoietic stem cells. Dr. Quinones investigates donor lymphocytes, graft-versus-leukemia and graft-versus-host disease.
Dr. Robert Garcea studies the use of recombinant viral proteins for immunization against papillomavirus in cervical cancer prevention. Dr. Timothy Garrington studies signal transduction pathways in cell cycle regulation, function and oncogenesis. Dr. Lia Gore works on clinical trials for novel cancer therapeutics, with a particular interest in the treatment of leukemia. She conducts basic science and translational studies of new agents and also works in the Phase I Development Therapeutics at the University of Colorado Cancer Center. Dr. Nicholas Foreman, together with Dr. Julie Ley, investigates novel therapies targeting abnormal ganglioside expressions in glioblastomas. Dr. Michael Jordan is exploring the strategy of directly attacking macrophages as a means of treating autoimmune hemolytic anemia (AHIA). Dr. Douglas Graham investigates the use of tyrosine kinases as biologic markers and therapeutic targets of pediatric cancers.
Dr. Daniel Ambruso investigates mechanisms regulating bactericidal activity of human neutrophils and monocytes. He also studies neutrophil function in thermal injury/trauma, chronic granulomatous disease and platelet activating factor generation in stored blood components. Dr. Taru Hays' research studies include hemolytic uremic syndrome, iron deficiency in adolescents, pediatric idiopathic thrombocytopenic purpura and thrombosis. Dr. Christopher Silliman studies the production of neutrophil priming agents generated by blood storage and signal transduction mechanisms in activation of neutrophil oxidase. Dr. Rachelle Nuss is collaborating with Dr. Silliman in the role of neutophil in acute chest syndrome of sickle cell disease. Dr. Marilyn Manco-Johnson researches hemostasis and thrombosis. Current projects examine evaluation and prevention of joint disease, prophylactic factor VIII replacement, isotopic synovectomy, surgical interventions and outcomes analysis.
The Experimental Therapeutics Program (ETP) within the Section promotes the development, scientific support and clinical translation of promising therapies for the treatment of children, adolescents and young adults with cancer and related disorders. The ETP is the only comprehensive basic and translational research-based program that can provide direct access to and application of these resources to the clinical care of pediatric, adolescent and young adult cancer patients in a twelve-state region by enrolling patients in phase I and phase II clinical trials. Because of strong academic affiliations locally, nationally and internationally, the ETP can provide access to new treatments and treatment modalities only available at a few highly select academic institutions around the US and Canada.
|
|
